Kim Forest Enterprise Co., Ltd.

Equities

6645

TW0006645005

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. 18:00:00 2024-05-30 EDT 5-day change 1st Jan Change
37 TWD -2.63% Intraday chart for Kim Forest Enterprise Co., Ltd. -1.33% +0.27%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kim Forest Enterprise Co., Ltd.(TWSE:6645) added to Taiwan TAIEX Index CI
Kim Forest Enterprise Co., Ltd. Appoints Daniel Huang as Chief Executive Officer CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Kim Forest's H1 Profit Rockets 148% as Revenue Hits Record-High MT
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019 CI
Kim Forest Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Chart Kim Forest Enterprise Co., Ltd.
More charts
KIM FOREST ENTERPRISE CO., LTD. is a Taiwan-based company mainly engaged in sale of biomedical products and provision of genetic testing and analysis services. The Company operates through two segments. The Biomedical Experiment Products segment is engaged in provision of laboratory equipment, reagents, supplies and equipment maintenance services. Main products include filter type microplate spectrophotometer, polymerase chain reaction (PCR) molecular biology experiment related equipment and reagents, equipment and reagents for separating cell, protein and nucleic acids, rapid DNA detection reagent and others. The Biotechnology and Genetic Testing segment is engaged in provision of whole genome sequencing (WGS) and whole exome sequencing(WES) tumor analysis services, RNA sequencing analysis, and new drug development system and check services.
More about the company
  1. Stock Market
  2. Equities
  3. 6645 Stock
  4. News Kim Forest Enterprise Co., Ltd.
  5. Kim Forest's H1 Profit Rockets 148% as Revenue Hits Record-High